Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL in metastatic urothelial carcinoma
NCT04383067Phase 2Unknown
- Sponsor
- Sheba Medical Center
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in urothelial carcinoma (UC), sponsored by Sheba Medical Center. Status: unknown.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04383067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383067.